Clinical Trial Update: Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating anlotinib in advanced and refractory natural killer / T-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasal-type Natural Killer T-cell Lymphoma
• Natural Killer T-cell Lymphoma

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type | Phase 2 | Status: COMPLETED